The tyrosine kinase inhibitor nilotinib has antineoplastic activity in prostate cancer cells but up-regulates the ERK survival signal-Implications for targeted therapies
| Image |  |
|---|---|
| Description | scientific article |
| Author/s |
author: Boris Hadaschik Markus Hohenfellner |
| Publication date | July 2, 2014 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |